Viking Therapeutics, Inc.
$37.08+2.0%YTD+4.3%1Y+15.6%
Mentions · last 7 days
451-4%
Price updated 1h ago·X counts updated 1d ago
AI verdict & sentimentAI analysisGenerated by AI from underlying data
Today's AI verdict on what's driving $VKTX, plus how loud the X conversation is and which way it's leaning.
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Biotechnology sits in its cycle right now — and what that implies for $VKTX.
Biotechnology
No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.
What this means for $VKTX
Partial — Develops GLP-1/GIP receptor agonists for obesity and NASH in both subcutaneous and oral formulations; the GLP-1 pipeline bifurcation and ADA oral formulation competition creates tailwinds for one product line, not the full operation.
Top industry ETF
$IBBiShares Biotechnology ETF
+11.9%YTD
+44.0%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
-7.0How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
-100%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
-10.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
-71.3%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q1 2026Apr 29, 2026$-1.37$-1.01-35.6%
Q4 2025Feb 11, 2026$-1.38$-0.89-55.1%
Q3 2025Oct 22, 2025$-0.81$-0.70-15.7%
Q2 2025Jul 23, 2025$-0.58$-0.44-31.8%
Next earningsWed, Jul 29·consensus EPS $-1.21
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-1.37$-114.0M
Q4 FY25$0———$-1.38$-85.3M
Q3 FY25$0———$-0.81$-94.0M
Q2 FY25$0———$-0.58$-47.1M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$7.2M$7.2M – $7.2M-$4.75-$5.78 – -$3.859
FY27$7.3M$7.3M – $7.3M-$4.77-$6.84 – -$2.3710
FY28$161.5M$161.5M – $161.5M-$3.91-$6.76 – -$0.2616
FY29$474.5M$474.5M – $474.5M-$1.73-$1.73 – -$1.7315
FY30$1.2B$1.2B – $1.2B$2.16$2.16 – $2.1615
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.66%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+9.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+8.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatMid float · 112.9M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.665-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.
Insider activity
Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.
SEC filings
Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.
Recent material filings
3New insider — initial holdingsJun 33
AI summary
8-KShareholder voteMay 268-K — Item 5.07: Shareholder vote
AI summary
+ 9 other (2 13Gs · 2 earnings 8-Ks · 2 proxys · 1 10-Q) in window
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to KnowViking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to KnowViking Therapeutics: Still Cheap, But Watch Double TopViking Therapeutics (VKTX) Price Forecast: Bottoming Pattern Signals Growing StrengthIs This Biotech Stock a Buy After Its Massive Rally?
In themes
Explore the broader themes this ticker is being talked about under.
More in Biotechnology
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · top 7 · last 7 days